5 Next-Generation Psychedelics Entering Clinical Trials This Year
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.
field trip health
-
-
Psychedelic Business Spotlight – May 13
This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.
-
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
-
Psychedelic Business Spotlight – April 29
This week in psychedelic business news: Field Trip Health splits in two, Tryp Therapeutics commences study, and Optimi Health celebrates new facility.
-
Psychedelic Business Spotlight – April 8
This week in psychedelic business news: Field Trip Health secures a patent; Core One Labs seeks more retail investors; a new CEO takes over GABA Therapeutics.
-
My Favorite Psychedelic Stocks: Part 1
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
-
Psychedelic Business Spotlight – March 4
This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory Council; Incannex pursues virtual reality psychedelic therapy.
-
Psychedelic Business Spotlight – February 25
This week in psychedelic business news: Core One cheapens psilocybin production; Field Trip eyes Oregon; Small Pharma advances DMT.
-
Psychedelic Business Spotlight — January 14
This week in psychedelic business news: Another psychedelics company starts trading on OTCQB; another ketamine trial delivers; and another patent is issued.
-
Is ‘The Trip’ Essential to The Psychedelic Experience?
Biology and experience are tough to separate, but some researchers are exploring the possibility of non-hallucinogenic psychedelics as a mental health treatment. This begs the question: what do we lose, and what do we gain when we take the trip out of the psychedelic experience?
